Homeopathy has been demonstrated to be safe and effective for a variety of health conditions in scientific research studies from across the globe.  

Anxiety:

A French study demonstrated that patients with anxiety and depression disorders who consulted a General Practitioner specializing in Homeopathy were more likely to have clinical improvement and reported less psychotropic drug use then patients who consulted with General Practitioners practicing conventional medication. 

This randomized, double-blind, placebo controlled study of 30 patients suffering from anxiety and depression showed statistically significant improvements in the Homeopathy group’s scores on emotional assessment instruments after 16 weeks of care. 

Attention Deficit and Hyperactivity Disorder:

A meta-analysis of six studies in the journal Pediatric Research of individualized homeopathy showed a clinically relevant and statistically robust effect in the treatment of ADHD.

Chronic Fatigue Syndrome:

A randomized, controlled, triple-blind trial of the efficacy of homeopathic treatment for chronic fatigue syndrome demonstrated that Homeopathy helped reduce patient scores on the Multidimensional Fatigue Inventory and the Functional Limitations Profile, both used to assess the impact of chronic fatigue syndrome. More people in the homeopathic medicine group showed clinical improvement on all primary outcomes related to chronic fatigue syndrome.  

Premenstrual Syndrome: 

In one study, individually prescribed homeopathic medicines were associated with significantly greater improvement of premenstrual symptoms in women with PMS, compared to placebo.  

Depression:

Two placebo-controlled double-blinded trials suggest homeopathic remedies might be comparable to antidepressants and superior to placebo in depression, and patients treated by homeopathy reported improvements in depression.  

Urinary Tract Infections:

An individual case series suggests a possible benefit of individualized homeopathic treatment for female patients with recurrent urinary tract infections. 

Supporting Cancer Patients:

A prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter, phase III study evaluated the possible effects of additive homeopathic treatment compared to placebo in patients with stage IV advanced non-small cell lung cancer (NSCLC), with respect to Quality of Life (QoL). The study found that QoL as well as functional and symptom scales showed significant improvement in the homeopathy group when compared with placebo after 9 and 18 weeks of homeopathic treatment. The median survival time was significantly longer in the homeopathy group (435 days) versus placebo (257 days; p = .010) as well as versus control (228 days; p < .001). Survival rate in the homeopathy group differed significantly from placebo (p = .020) and from control (p < .001). The symptoms (nausea, shortness of breath, loss of appetite, etc.) were also rated significantly better in the homeopathy group.